Mergers & Acquisitions ·
Chemomab and Scipher amend merger agreement to reduce combined company shares from 10M to 5M
CMMBChemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd. and its partners executed Amendment No. 2 to the Agreement and Plan of Merger with Scipher Medicine Corporation, adjusting the Domestication Exchange Ratio for Chemomab's redomiciliation into the U.S. The amendment reduces the number of Chemomab Parent shares outstanding immediately following the merger from 10,000,000 to 5,000,000. This technical change does not alter the transaction consideration or economic value but updates share counts and CVR information rights. Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing immunotherapies for cancer.